Fourth Quarter Financial Highlights

BioNTech SE has announced a significant achievement in its fourth quarter of fiscal 2024, reporting a total revenue of €1.2 billion. This figure, despite marking a 24.4% decrease from the previous year, has exceeded analysts' expectations. The company's net profit for the quarter stood at €259.5 million, a decrease from €457.9 million in the same period last year. Diluted earnings per share (EPS) were reported at €1.08, down from €1.88 a year ago.

Full Fiscal Year Overview

For the entire fiscal year 2024, BioNTech disclosed total revenues of €2.7 billion, a decline from €3.8 billion in 2023. The diluted loss per share was noted at €2.77, contrasting with the earnings per share of €3.83 in the previous year.

CEO's Statement and Market Reaction

"The year 2024 has been pivotal for BioNTech, with significant advancements in our oncology pipeline. This includes the initiation of global Phase 3 clinical trials for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 and key updates from our mRNA cancer immunotherapy programs," stated CEO Ugur Sahin. Following the earnings announcement, BioNTech's shares experienced a 1.93% drop in premarket trading in the United States.